Display Settings:

Format

Send to:

Choose Destination
    Clin Pharmacol Ther. 2007 Aug;82(2):137-42.

    Pharmacometrics and the transition to model-based development.

    Source

    Cognigen Corporation, Williamsville, New York, USA. ted.grasela@cognigencorp.com

    Abstract

    As the transition to model-based drug development continues, pharmacometric analysis will have an increasingly important role across the entire life cycle of drug discovery, development, regulatory approval, and commercialization. For this reason, pharmacometrics can--and should--have an integrating function in the transformation to model-based development. This essay describes an approach for formalizing the pharmacometrics process using the disciplines encompassed by enterprise engineering.

    PMID:
    17632539
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk